1377049-84-7 Velpatasvir Pharmaceutical Raw Materials Active Pharmaceutical Ingredients

Details:

Velpatasvir Pharmaceutical Raw Materials Active Pharmaceutical Ingredients

Product details:

Treat all six main HCV genotypes in the first scheme, velpatasvir, a new drug, and was the first to treat all six main type of HCV.

The FDA's drug evaluation and research center director of antimicrobial products in said: "the approval for a broad range of patients with chronic hepatitis c provides a treatment and treatment options."Priority review.

velpatasvir, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.

In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3.

Sofosbuvir works by interfering with the activity of an enzyme (NS5B) used by HCV-infected cells. Velpatasvir works by interfering with another HCV enzyme called NS5A.

Results:

Overall, 99% of participants who took sofosbuvir + velpatasvir were cured of hepatitis C 12 weeks after the cessation of therapy. Such high cure rates occurred regardless of the genotype or subtype of HCV. This cure, referred to as a sustained virological response, is written as SVR12. None of the participants who received placebo were cured.